Home/Filings/3/0001209191-21-007983
3//SEC Filing

5AM Ventures VI, L.P. 3

Accession 0001209191-21-007983

CIK 0001817229other

Filed

Feb 3, 7:00 PM ET

Accepted

Feb 4, 9:50 PM ET

Size

14.7 KB

Accession

0001209191-21-007983

Insider Transaction Report

Form 3
Period: 2021-02-04
Holdings
  • Series A-2 Preferred Stock

    (indirect: See Footnote)
    Common Stock (3,308,822 underlying)
  • Series B Preferred Stock

    (indirect: See Footnote)
    Common Stock (1,414,026 underlying)
  • Series B Preferred Stock

    (indirect: See Footnote)
    Common Stock (1,414,026 underlying)
Holdings
  • Series B Preferred Stock

    (indirect: See Footnote)
    Common Stock (1,414,026 underlying)
  • Series B Preferred Stock

    (indirect: See Footnote)
    Common Stock (1,414,026 underlying)
  • Series A-2 Preferred Stock

    (indirect: See Footnote)
    Common Stock (3,308,822 underlying)
Holdings
  • Series B Preferred Stock

    (indirect: See Footnote)
    Common Stock (1,414,026 underlying)
  • Series A-2 Preferred Stock

    (indirect: See Footnote)
    Common Stock (3,308,822 underlying)
  • Series B Preferred Stock

    (indirect: See Footnote)
    Common Stock (1,414,026 underlying)
Holdings
  • Series A-2 Preferred Stock

    (indirect: See Footnote)
    Common Stock (3,308,822 underlying)
  • Series B Preferred Stock

    (indirect: See Footnote)
    Common Stock (1,414,026 underlying)
  • Series B Preferred Stock

    (indirect: See Footnote)
    Common Stock (1,414,026 underlying)
Holdings
  • Series B Preferred Stock

    (indirect: See Footnote)
    Common Stock (1,414,026 underlying)
  • Series A-2 Preferred Stock

    (indirect: See Footnote)
    Common Stock (3,308,822 underlying)
  • Series B Preferred Stock

    (indirect: See Footnote)
    Common Stock (1,414,026 underlying)
Footnotes (3)
  • [F1]Each share of Series A-2 Preferred Stock and Series B Preferred Stock is convertible at any time at the option of the holder, without payment of additional consideration, into Common Stock, on a 13.6-for-one basis, has no expiration date and will automatically convert into shares of Common Stock upon the closing of the Issuer's initial public offering.
  • [F2]The shares are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI and Mr. Schwab disclaims beneficial ownership of the shares of Common Stock held directly by Ventures VI, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the issuer and files separate Section 16 reports.
  • [F3]The shares are directly held by 5AM Opportunities I, L.P ("Opportunities LP"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities LP. Andrew J. Schwab and Dr. Kush Parmar are the managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities LP. Each of Opportunities GP and Mr. Schwab disclaims beneficial ownership of the shares of Common Stock held directly by Opportunities LP, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the issuer and files separate Section 16 reports.

Issuer

Vor Biopharma Inc.

CIK 0001817229

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001753037

Filing Metadata

Form type
3
Filed
Feb 3, 7:00 PM ET
Accepted
Feb 4, 9:50 PM ET
Size
14.7 KB